J&J Q3 earnings fall short of expectations as stock slides, BMS reports mixed trial outcomes and RevMed highlights subgroup data

Johnson & Johnson reported third‑quarter results that met analyst forecasts, driven by its innovative medicines segment, but the company’s stock dropped about 4% as the med‑tech division lagged behind expectations.

Bristol Myers Squibb saw a mixed week of data. A low‑dose regimen in a Phase 3 idiopathic pulmonary fibrosis study showed a win, while a higher dose failed to improve exhalation capacity. The company also celebrated a clear Phase 3 success for RYZ‑101, an asset acquired in its $4.1 billion purchase of RayzeBio.

Revolution Medicines announced that its newly approved pancreatic cancer therapy performs better in patients whose tumors carry specific mutations, highlighting a promising subgroup analysis. Meanwhile, Caribou Biosciences appears to be scaling back operations, suggesting a possible exit from certain projects.